• J3/31 A-3 Khiri Extention Malviya Nagar, New Delhi-17
  • macnispharma@gmail.com
  • Working Hours - Mon - Fri: 9:30 - 18:30

Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment

Abstract

Background: After the failure of clarithromycin- and bismuth-based quadruple therapy (CBQT), levofoxacin- and

bismuth-based quadruple therapy (LBQT) is recommended for Helicobacter pylori eradication. We compared the ef￾

cacies of second-line tailored bismuth-based quadruple therapy (TBQT) and empirical LBQT.

Methods: Patients with CBQT failure were randomly assigned to receive TBQT or LBQT for 14 days. All patients under￾

went endoscopy for culture-based antibiotic susceptibility testing. Patients in the TBQT group exhibiting levofoxacin

susceptibility were randomized to receive amoxicillin, levofoxacin, esomeprazole, and colloidal bismuth pectin (ALEB)

or amoxicillin, furazolidone, esomeprazole, and colloidal bismuth pectin (AFEB) for 14 days; patients with levofoxacin

resistance received AFEB.

Results: From May 2016 to June 2019, 364 subjects were enrolled. Eradication rates were signifcantly higher in the

TBQT group (n=182) than in the LBQT group (n=182) according to both intention-to-treat (ITT) analysis (89.6% vs.

64.8%, P<0.001) and per protocol (PP) analysis (91.1% vs. 67.8%, P<0.001). Among patients in the TBQT group with

levofoxacin susceptibility, eradication rates were similar in the ALEB (n=51) and AFEB (n=50) subgroups accord￾

ing to both the ITT (86.3% vs. 90.0%, P=0.56) and PP (88.0% vs. 90.0%, P=0.75) analyses. Isolated clarithromycin and

levofoxacin resistance rates were 57.7% and 44.5%, respectively. The total clarithromycin and levofoxacin resistance

rate in strains with dual or triple resistance was 35.7%.

Conclusions: TBQT was more efective than LBQT as a second-line strategy after CBQT failure. In the absence of anti￾

biotic susceptibility testing, AFEB therapy might be used as a rescue therapy to eradicate H. pylori and avoid levofoxa￾

cin resistance.

Trial registration: Chinese Clinical Trial Registry (www.chictr.org.cn): ChiCTR1900027743.